- Home
- AZN
AZN
AstraZeneca PLC
as 02-21-2025 4:00pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 223.3B | IPO Year: | 1993 |
| Target Price: | $89.75 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 4.50 | EPS Growth: | 18.11 |
| 52 Week Low/High: | $62.75 - $87.68 | Next Earning Date: | 02-06-2025 |
| Revenue: | $54,073,000,000 | Revenue Growth: | 18.03% |
| Revenue Growth (this year): | 8.02% | Revenue Growth (next year): | 5.78% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
AstraZeneca PLC (AZN): Among the Best Global Stocks to Buy According to Hedge Funds
Pharmaceutical Technology
a day ago
FibroGen sells China unit to AstraZeneca for $160m
Zacks
2 days ago
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
Zacks
2 days ago
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
MT Newswires
2 days ago
FibroGen to Sell China Unit to AstraZeneca for $160 Million
Insider Monkey
2 days ago
Here’s Why AstraZeneca PLC (AZN) Traded Lower in Q4
Reuters
2 days ago
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
BioPharma Dive
2 days ago
AstraZeneca deepens China presence with FibroGen deal
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.